08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

CVBT-141B: Phase IIb data

In a double-blind Phase IIb trial, diabetic wounds treated with CVBT-141B achieved 100% closure in <=5 months compared with 33% of the placebo group whose wounds remained open. Additionally, 57% of patients in the CVBT-141B...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

CVBT-141B: Phase IIa data

In a double-blind Phase IIa trial, CVBT-141B healed diabetic wounds about 4.5 times faster than placebo plus standard of care. No significant drug-related adverse events were observed. CardioVascular plans to apply for Fast Track Designation...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

CardioVascular BioTherapeutics, Merck deal

CardioVascular received an exclusive license to use clinical and scientific data from Merck concerning the therapeutic use of fibroblast growth factor-1 (FGF-1) to treat diabetic wounds. CardioVascular plans to use the data as part of...
08:00 , Feb 8, 2010 |  BioCentury  |  Finance

Ironed Out

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) didn't get the $1.2 billion pre-money and $1.4 billion post-money valuation it had hoped for, nor did it raise the $250 million it would have at the mid-point of its range....
08:00 , Nov 24, 2008 |  BC Week In Review  |  Company News

CardioVascular BioTherapeutics, Cardio Neo-Genesis L.P. deal

CardioVascular will receive up to $15 million from Cardio Neo-Genesis to fund clinical development of CardioVascular's CVBT-141H to treat coronary heart disease (CHD). In return, Cardio Neo-Genesis is eligible for 5% royalties capped at 20...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Clinical News

FGF-1: Phase II started

The company began an open-label, dose-escalation, international Phase II trial to evaluate FGF-1 injected directly into the hearts of 120 patients with stable angina who were not suitable candidates for interventional therapy or bypass surgery....
07:00 , May 26, 2008 |  BC Week In Review  |  Company News

CardioVascular BioTherapeutics, ProDerm L.P. deal

CardioVascular will receive $1-$10 million from ProDerm to fund future clinical trials of CVBT-141B to treat diabetic foot ulcers and venous stasis leg wounds. In return, ProDerm is eligible for 10% royalties on resulting revenues...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

CardioVascular BioTherapeutics cardiovascular news

CVBT engaged the Bruckner Group to assist the company in finding a joint commercialization partner for CVBT-141H to treat severe coronary heart disease. The human fibroblast growth factor-1 (FGF-1) inducer of angiogenesis is in Phase...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Clinical News

FGF-1: Phase I data

In a U.S. Phase I trial in 21 patients, FGF-1 was safe and had no significant adverse events when injected directly into the heart muscle of patients with severe heart disease. FGF-1 patients had a...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Clinical News

CVBT-141B: Phase I data

In a Phase I trial in 8 patients with either diabetic or venous stasis ulcers, topical CVBT-141B was well tolerated. CardioVascular BioTherapeutics Inc. (CVBT), Las Vegas, Nev.   Product: CVBT-141B   Business: Dermatology   Molecular...